Principal Investigator
Hadar Lev-Tov
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240593
Clinical Trial Summary
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients and adolescent patients with moderate to severe hidradenitis suppurativa (RECHARGE-1)
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other